DDInter438 DDInter1940
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vismodegib
Conivaptan {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Vismodegib
Conivaptan {u} (Compound) causes {v} (Side Effect) Dehydration
Dehydration {u} (Side Effect) is caused by {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Conivaptan (Compound) resembles Tolvaptan (Compound) and Tolvaptan (Compound) resembles Vismodegib (Compound)
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vismodegib (Compound)
Conivaptan (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Conivaptan (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Conivaptan (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Conivaptan (Compound) resembles Tolvaptan (Compound) and Tolvaptan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Vismodegib (Compound)
Conivaptan (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Tolvaptan (Compound) and Tolvaptan (Compound) resembles Vismodegib (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)